# Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

> **NCT01714726** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 121 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** MEDI2070
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01714726
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-01
- **Primary completion:** 2014-05-20
- **Final completion:** 2016-12-14
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2021-05-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01714726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01714726, "Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01714726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*